Provided are methods of treating Parkinson’s disease or Parkinsonism by administering an adenosine A2a receptor antagonist in combination with a dopamine precursor or a dopamine receptor agonist. A preferred adenosine A2a receptor antagonist is 4-hydroxy-4-methylpiperidine-1-carboxylic acid-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide. A preferred dopamine precursor is levodopa and preferred dopamine receptor antagonists are apomorphine pramipexole, bromocriptine, cabergoline, ropinirole or rotigotine. Provided are methods of treating cognition impairment or decline or of enhancing cognition by administering 4-hydroxy-4-methylpiperidine-1-carboxylic acid-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide.
A2a antagonists as cognition and motor function enhancers